title: The effects of potassium channel openers and blockers on the specific binding sites for [3H]glibenclamide in rat tissues.
abstract: The effects of K+ channel openers (PCOs), NIP-121, levcromakalim and nicorandil, and the blockers of the specific binding sites for [3H]glibenclamide, ATP-sensitive K+ channel blocker, were investigated in rat brain and cardiac ventricle membrane preparations. When the microsomes were incubated with [3H]glibenclamide, the specific glibenclamide binding was fully inhibited by unlabeled glibenclamide (1 microM) and apamin (100 microM). However, the specific glibenclamide binding was not influenced by excess NIP-121, levcromakalim and nicorandil, although glibenclamide antagonized the increase in the 86Rb+ efflux by PCOs. On the other hand, the binding of [3H]glibenclamide after a long pre-incubation (60 min) at 37 degrees C with NIP-121 and levcromakalim at pharmacological effective concentrations (10 nM to 1 microM) was significantly influenced. Both PCOs partially reduced both Kd and Bmax values of the specific [3H]glibenclamide binding in a concentration-dependent manner that was not regulated by GTP gamma S. The dose-effect relationships for the Bmax's of NIP-121 and levcromakalim seemed similar to those for vasorelaxation. These findings indicate that the pharmacological effect of PCO may be caused by the binding to its own specific sites but not to the specific sulfonylurea sites. The binding of PCOs may inhibit, in a negative allosteric manner the binding of sulfonylureas.
authors.affiliation: Shiraoka Research Station of Biological Science, Nissan Chemical Industries, Ltd., Saitama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yamashita
authors.forename: Y
authors.initials: Y
authors.lastname: Masuda
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
mesh_terms: D000818:Animals; D001665:Binding Sites; D001921:Brain / Q000187:drug effects*; D002462:Cell Membrane / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005905:Glyburide; D006352:Heart Ventricles / Q000187:drug effects*; D008297:Male; D009119:Muscle Contraction; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology; D020108:Nicorandil; D010069:Oxadiazoles / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000819:agonists*; D051381:Rats; D017208:Rats, Wistar; D012413:Rubidium / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D010069:Oxadiazoles; D010880:Piperidines; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D014665:Vasodilator Agents; D009536:Niacinamide; D020108:Nicorandil; C070366:NIP 121; D012413:Rubidium; D005905:Glyburide